Physician profile
Henry Tam
NPI 1306834247
$15,455.73
in general payments reported to CMS, 2019-2025
60 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $2,021 · 2021: $2,637 · 2022: $1,995 · 2023: $2,573 · 2024: $2,123 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,595 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,594.70 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,271.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,126.43 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,056.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,004.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $966.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $775.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.98 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $564.50 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $536.57 | 2019-2025 | |
| Astellas Pharma US INC | $482.65 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $465.03 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $426.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $356.64 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $355.58 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $347.76 | 2019-2025 | Rexulti |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Tam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.